Showing results (1-10 of 303) with videos related to
Sort By:
Pageof 31
Science (New York, N.Y.)|December 9, 2021
Oncolytic virotherapy as immunotherapyAlan Melcher, Kevin Harrington, Richard VileMolecular Therapy : the Journal of the American Society of Gene Therapy|August 20, 2009
Cell carriers for oncolytic viruses: Fed Ex for cancer therapyCandice Willmon, Kevin Harrington, Timothy Kottke, et al.Current Cancer Drug Targets|March 6, 2010
The biology of the sodium iodide symporter and its potential for targeted gene deliveryMohan Hingorani, Christine Spitzweg, Georges Vassaux, et al.Molecular Cancer|February 23, 2011
Pro-inflammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-κB mediated and supports innate and adaptive anti-tumour immune primingLynette Steele, Fiona Errington, Robin Prestwich, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapyFiona Errington, Andrew Bateman, Tim Kottke, et al.Molecular Therapy Oncolytics|March 5, 2021
Oncolytic Reovirus-Mediated Recruitment of Early Innate Immune Responses Reverses Immunotherapy Resistance in Prostate TumorsNicola E Annels, Guy R Simpson, Mick Denyer, et al.Molecular Therapy : the Journal of the American Society of Gene Therapy|October 28, 2010
Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideCandice Willmon, Rosa M Diaz, Phonphimon Wongthida, et al.Journal for Immunotherapy of Cancer|March 8, 2019
Radiotherapy enhances responses of lung cancer to CTLA-4 blockadeAnna Wilkins, Fiona McDonald, Kevin Harrington, et al.Lancet (London, England)|September 20, 2025
Oncolytic viruses as anticancer agents: clinical progress and remaining challengesElizabeth Appleton, E Antonio Chiocca, Guy Ungerechts, et al.Cancer Immunology, Immunotherapy : CII|December 7, 2007
Autologous versus allogeneic peptide-pulsed dendritic cells for anti-tumour vaccination: expression of allogeneic MHC supports activation of antigen specific T cells, but impairs early naïve cytotoxic priming and anti-tumour therapyAlison Merrick, Rosa Maria Diaz, Dearbhaile O'Donnell, et al.Pageof 31